Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Environmental Health Perspectives|September 12, 2013
Childhood cancer and traffic-related air pollution exposure in pregnancy and early lifeJulia E Heck, Jun Wu, Christina Lombardi, et al.
Environmental Research|February 13, 2014
Prenatal air pollution exposure and ultrasound measures of fetal growth in Los Angeles, CaliforniaBeate Ritz, Jiaheng Qiu, Pei-Chen Lee, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2023
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanomaDrew W Rasco, Theresa Medina, Pippa Corrie, et al.
Nature Communications|May 14, 2016
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrantJill M Spoerke, Steven Gendreau, Kimberly Walter, et al.
The Lancet. Oncology|May 9, 2016
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trialIan E Krop, Ingrid A Mayer, Vinod Ganju, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Neuro-Oncology|December 19, 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trialKarsten Nysom, Lindsay B Kilburn, Sarah E S Leary, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Pageof 2